Free tool
Stocks listed on XETRA
We cover 18 companies listed on XETRA. The median market value in the group is $1.71B. Across the group, the median move over the past trading day is +0.69%. Price change over the past year runs from −33.1% to +62.9% across the middle 80 percent of the group, with a median of −4.6%.
Other lists in this group
Table
18 of 1,273 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| QIA.DE | Qiagen N.V. | $8.99B | Mid cap | −6.73% | Nov 4, 2026 |
| OBCK.DE | Ottobock SE & Co. KGaA | $4.40B | Mid cap | +0.68% | Nov 12, 2026 |
| BBZA.DE | BB Biotech AG | $3.87B | Mid cap | +7.22% | Oct 23, 2026 |
| 22Z.DE | Zealand Pharma A/S | $3.37B | Mid cap | −28.16% | Nov 12, 2026 |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% | Nov 12, 2026 |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% | Nov 13, 2026 |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% | Oct 29, 2026 |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +27.27% | Nov 12, 2026 |
| GXE.DE | Lakefront Biotherapeutics NV | $1.93B | Small cap | −44.50% | Nov 12, 2026 |
| RDC.DE | Redcare Pharmacy NV | $1.49B | Small cap | −23.82% | Oct 29, 2026 |
| RHK.DE | RHÖN-KLINIKUM Aktiengesellschaft | $1.14B | Small cap | +24.49% | Nov 5, 2026 |
| EUZ.DE | Eckert & Ziegler SE | $952.11M | Small cap | −24.60% | Nov 12, 2026 |
| EVT.DE | Evotec SE | $694.87M | Small cap | −45.75% | Nov 5, 2026 |
| ILM1.DE | Medios AG | $324.14M | Small cap | −26.32% | Nov 10, 2026 |
| SBS.DE | Stratec SE | $322.43M | Small cap | −16.91% | Nov 12, 2026 |
| XUP.DE | Genfit S.A. | $258.22M | Small cap | +166.82% | Sep 29, 2026 |
| IDD.DE | Innate Pharma S.A. | $243.27M | Small cap | −2.52% | Sep 17, 2026 |
| PSH0.DE | Sernova Biotherapeutics Inc | $30.82M | Micro cap | −27.68% | Sep 10, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.